Table 2.

Patterns of fidaxomicin (FDX) use

Pattern of FDX use		Hospital (total number of beds)
		A (1100)	B (1000)	Ca (1806)	D (426)	E (890)	F (1187)	G (591)
		First line in all episodes	First line in all episodes	Used in selected episodes onlyb	First line for recurrence only	Used in selected episodes onlyc	Used in selected episodes onlyd	Used in selected episodes onlye
Time period	Description of treatment	No. of primary episodes
Pre-FDX	Non-FDX	66	98	79a	70	117	89	112
Post-FDX	Non-FDX	–	–	120	52	47	30	55
	FDX first line	27	62	10	1	17	52	6
	FDX not first line	5	2	10	3	29	7	8
	All treatments	32	64	140a	56	93	89	68
No. of recurrences
Time period	Diagnostic approach	Clinical + toxin	Clinical	Clinical + toxin	Clinical	Clinical	Clinical	Clinical + toxin
Pre-FDX	Non-FDX	7	23	5a	5	22	16	9
Post-FDX	Non-FDX	–	–	16	–	7	6	2
	FDX first line	2	2	10	1	3	5	1
	FDX not first line	–	–	5	–	2	–	1
	All treatments	2	2	31a	1	12	11	4

^aData represent a sample of all episodes

^bRecurrences and selected primary episodes according to microbiologist or infectious diseases consultant discretion

^cAll C. difficile toxin-positive patients except if: relative contraindication (age, severe renal failure, other medication), patient already recovered, patient discharged

^dAll C. difficile toxin-positive patients aged over 75 years old: first line; under 75 years old: for relapse and/or multiple co-morbidities and needing other antibiotics

^eRecurrences and primary episodes in patients with risk factors that made a recurrence likely, e.g. immunosuppressed patients, those with several co-morbidities